Position statement regarding COVID-19 tests evaluated by PHE
Updated 9 June 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/position-statement-regarding-covid-19-tests-evaluated-by-phe/position-statement-regarding-covid-19-tests-evaluated-by-phe
PHE’s evaluation of commercial products for diagnosing COVID-19 infection and detecting the presence of antibodies against COVID-19 have been carried out under contract and are primarily for PHE’s own use. The reports of such evaluations are shared with the manufacturers and other external organisations solely for their information.
PHE may also undertake evaluations on behalf of the government’s COVID-19 Testing Advisory Group and will in that case report the results back to this group.
The manufacturers are made aware of the results of our evaluations prior to issue but have no editorial rights over the content of our reports except to ensure factual accuracy.
It should be noted that PHE is not a regulatory body and that PHE does not issue accreditation of any testing laboratories or provide approvals, validations or endorsements of any particular products including any COVID-19 diagnostic assay.
PHE’s name and logo are proprietary to PHE and cannot be used for the purpose of commercial promotion of any particular product.
The terms and conditions under which PHE’s evaluations are carried out expressly prohibits any such use which could be a breach of contract in relation to PHE and may be misleading in relation to potential customers.